Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

• Egile Nagusiak: Hani Jouihan (Egilea), Sarah Will (Egilea), Silvia Guionaud (Egilea), Michelle L. Boland (Egilea), Stephanie Oldham (Egilea), Peter Ravn (Egilea), Anthony Celeste (Egilea), James L. Trevaskis (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2017-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects...